Prostate Cancer - Pipeline Review, H1 2015


#316352

1455pages

Global Markets Direct

$ 2500

In Stock

Prostate Cancer - Pipeline Review, H1 2015

Summary

Global Markets Directs, Prostate Cancer - Pipeline Review, H1 2015, provides an overview of the Prostate Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 11
Prostate Cancer Overview 12
Therapeutics Development 13
Prostate Cancer Therapeutics under Development by Companies 15
Prostate Cancer Therapeutics under Investigation by Universities/Institutes 36
Prostate Cancer Pipeline Products Glance 42
Prostate Cancer Products under Development by Companies 46
Prostate Cancer Products under Investigation by Universities/Institutes 74
Prostate Cancer Companies Involved in Therapeutics Development 80
Prostate Cancer Therapeutics Assessment 311
Drug Profiles 349
Prostate Cancer Recent Pipeline Updates 1053
Prostate Cancer Dormant Projects 1350
Prostate Cancer Discontinued Products 1386
Prostate Cancer Product Development Milestones 1394
Appendix 1403

List of Tables
Number of Products under Development for Prostate Cancer, H1 2015 64
Number of Products under Development for Prostate Cancer Comparative Analysis, H1 2015 65
Number of Products under Development by Companies, H1 2015 67
Number of Products under Development by Companies, H1 2015 (Contd..1) 68
Number of Products under Development by Companies, H1 2015 (Contd..2) 69
Number of Products under Development by Companies, H1 2015 (Contd..3) 70
Number of Products under Development by Companies, H1 2015 (Contd..4) 71
Number of Products under Development by Companies, H1 2015 (Contd..5) 72
Number of Products under Development by Companies, H1 2015 (Contd..6) 73
Number of Products under Development by Companies, H1 2015 (Contd..7) 74
Number of Products under Development by Companies, H1 2015 (Contd..8) 75
Number of Products under Development by Companies, H1 2015 (Contd..9) 76
Number of Products under Development by Companies, H1 2015 (Contd..10) 77
Number of Products under Development by Companies, H1 2015 (Contd..11) 78
Number of Products under Development by Companies, H1 2015 (Contd..12) 79
Number of Products under Development by Companies, H1 2015 (Contd..13) 80
Number of Products under Development by Companies, H1 2015 (Contd..14) 81
Number of Products under Development by Companies, H1 2015 (Contd..15) 82
Number of Products under Development by Companies, H1 2015 (Contd..16) 83
Number of Products under Development by Companies, H1 2015 (Contd..17) 84
Number of Products under Development by Companies, H1 2015 (Contd..18) 85
Number of Products under Development by Companies, H1 2015 (Contd..19) 86
Number of Products under Investigation by Universities/Institutes, H1 2015 88
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 89
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 90
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 91
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 92
Comparative Analysis by Late Stage Development, H1 2015 93
Comparative Analysis by Clinical Stage Development, H1 2015 94
Comparative Analysis by Early Stage Development, H1 2015 95
Comparative Analysis by Unknown Stage Development, H1 2015 96
Products under Development by Companies, H1 2015 97
Products under Development by Companies, H1 2015 (Contd..1) 98
Products under Development by Companies, H1 2015 (Contd..2) 99
Products under Development by Companies, H1 2015 (Contd..3) 100
Products under Development by Companies, H1 2015 (Contd..4) 101
Products under Development by Companies, H1 2015 (Contd..5) 102
Products under Development by Companies, H1 2015 (Contd..6) 103
Products under Development by Companies, H1 2015 (Contd..7) 104
Products under Development by Companies, H1 2015 (Contd..8) 105
Products under Development by Companies, H1 2015 (Contd..9) 106
Products under Development by Companies, H1 2015 (Contd..10) 107
Products under Development by Companies, H1 2015 (Contd..11) 108
Products under Development by Companies, H1 2015 (Contd..12) 109
Products under Development by Companies, H1 2015 (Contd..13) 110
Products under Development by Companies, H1 2015 (Contd..14) 111
Products under Development by Companies, H1 2015 (Contd..15) 112
Products under Development by Companies, H1 2015 (Contd..16) 113
Products under Development by Companies, H1 2015 (Contd..17) 114
Products under Development by Companies, H1 2015 (Contd..18) 115
Products under Development by Companies, H1 2015 (Contd..19) 116
Products under Development by Companies, H1 2015 (Contd..20) 117
Products under Development by Companies, H1 2015 (Contd..21) 118
Products under Development by Companies, H1 2015 (Contd..22) 119
Products under Development by Companies, H1 2015 (Contd..23) 120
Products under Development by Companies, H1 2015 (Contd..24) 121
Products under Development by Companies, H1 2015 (Contd..25) 122
Products under Development by Companies, H1 2015 (Contd..26) 123
Products under Development by Companies, H1 2015 (Contd..27) 124
Products under Investigation by Universities/Institutes, H1 2015 125
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 126
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 127
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 128
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 129
Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 130
Prostate Cancer Pipeline by 4SC AG, H1 2015 131
Prostate Cancer Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 132
Prostate Cancer Pipeline by AB Science, H1 2015 133
Prostate Cancer Pipeline by AbbVie Inc., H1 2015 134
Prostate Cancer Pipeline by Acino Pharma AG, H1 2015 135
Prostate Cancer Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 136
Prostate Cancer Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 137
Prostate Cancer Pipeline by ADC Therapeutics Sarl, H1 2015 138
Prostate Cancer Pipeline by Addex Therapeutics Ltd, H1 2015 139
Prostate Cancer Pipeline by Aduro BioTech, Inc., H1 2015 140
Prostate Cancer Pipeline by Advanced Cancer Therapeutics, H1 2015 141
Prostate Cancer Pipeline by Advantagene, Inc., H1 2015 142
Prostate Cancer Pipeline by Advaxis, Inc., H1 2015 143
Prostate Cancer Pipeline by Aeterna Zentaris Inc., H1 2015 144
Prostate Cancer Pipeline by Aileron Therapeutics, Inc., H1 2015 145
Prostate Cancer Pipeline by Akshaya Bio Inc., H1 2015 146
Prostate Cancer Pipeline by Alchemia Limited, H1 2015 147
Prostate Cancer Pipeline by Alethia Biotherapeutics Inc., H1 2015 148
Prostate Cancer Pipeline by Almac Discovery Limited, H1 2015 149
Prostate Cancer Pipeline by Ambrx, Inc., H1 2015 150
Prostate Cancer Pipeline by Amgen Inc., H1 2015 151
Prostate Cancer Pipeline by Amorfix Life Sciences Ltd., H1 2015 152
Prostate Cancer Pipeline by Anavex Life Sciences Corp., H1 2015 153
Prostate Cancer Pipeline by AndroScience Corporation, H1 2015 154
Prostate Cancer Pipeline by Angion Biomedica Corp., H1 2015 155
Prostate Cancer Pipeline by AntiCancer, Inc., H1 2015 156
Prostate Cancer Pipeline by Antigen Express, Inc., H1 2015 157
Prostate Cancer Pipeline by Antisense Therapeutics Limited, H1 2015 158
Prostate Cancer Pipeline by Aphios Corporation, H1 2015 159
Prostate Cancer Pipeline by APIM Therapeutics AS, H1 2015 160
Prostate Cancer Pipeline by Aptose Biosciences Inc., H1 2015 161
Prostate Cancer Pipeline by Armour Therapeutics Inc., H1 2015 162
Prostate Cancer Pipeline by Arno Therapeutics, Inc., H1 2015 163
Prostate Cancer Pipeline by ArQule, Inc., H1 2015 164
Prostate Cancer Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 165
Prostate Cancer Pipeline by Arrowhead Research Corporation, H1 2015 166
Prostate Cancer Pipeline by Ascenta Therapeutics, Inc., H1 2015 167
Prostate Cancer Pipeline by Astellas Pharma Inc., H1 2015 168
Prostate Cancer Pipeline by Astex Pharmaceuticals, Inc., H1 2015 169
Prostate Cancer Pipeline by AstraZeneca Plc, H1 2015 170
Prostate Cancer Pipeline by ATLAB Pharma SAS, H1 2015 171
Prostate Cancer Pipeline by Avipep Pty Ltd, H1 2015 172
Prostate Cancer Pipeline by Axelar AB, H1 2015 173
Prostate Cancer Pipeline by Azaya Therapeutics Incorporated, H1 2015 174
Prostate Cancer Pipeline by Bavarian Nordic A/S, H1 2015 175
Prostate Cancer Pipeline by Bayer AG, H1 2015 176
Prostate Cancer Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 177
Prostate Cancer Pipeline by Beta Pharma, Inc., H1 2015 178
Prostate Cancer Pipeline by BHR Pharma, LLC, H1 2015 179
Prostate Cancer Pipeline by BIND Therapeutics, Inc., H1 2015 180
Prostate Cancer Pipeline by Bio-Cancer Treatment International Limited, H1 2015 181
Prostate Cancer Pipeline by Bio-Path Holdings, Inc., H1 2015 182
Prostate Cancer Pipeline by BioMarin Pharmaceutical Inc., H1 2015 183
Prostate Cancer Pipeline by Bionature E.A. Ltd., H1 2015 184
Prostate Cancer Pipeline by Bionomics Limited, H1 2015 185
Prostate Cancer Pipeline by Biotest AG, H1 2015 186
Prostate Cancer Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 187
Prostate Cancer Pipeline by Boehringer Ingelheim GmbH, H1 2015 188
Prostate Cancer Pipeline by Bristol-Myers Squibb Company, H1 2015 189
Prostate Cancer Pipeline by Camurus AB, H1 2015 190
Prostate Cancer Pipeline by Celgene Corporation, H1 2015 191
Prostate Cancer Pipeline by CellCentric Ltd, H1 2015 192
Prostate Cancer Pipeline by Celldex Therapeutics, Inc., H1 2015 193
Prostate Cancer Pipeline by Cellectar Biosciences, Inc., H1 2015 194
Prostate Cancer Pipeline by Champions Oncology, Inc., H1 2015 195
Prostate Cancer Pipeline by Cimab S.A., H1 2015 196
Prostate Cancer Pipeline by Colby Pharmaceutical Company, H1 2015 197
Prostate Cancer Pipeline by Cold Genesys, Inc., H1 2015 198
Prostate Cancer Pipeline by Corcept Therapeutics Incorporated, H1 2015 199
Prostate Cancer Pipeline by Crescendo Biologics Limited, H1 2015 200
Prostate Cancer Pipeline by CureTech Ltd., H1 2015 201
Prostate Cancer Pipeline by CureVac GmbH, H1 2015 202
Prostate Cancer Pipeline by CytoVac A/S, H1 2015 203
Prostate Cancer Pipeline by CZ BioMed Corp, H1 2015 204
Prostate Cancer Pipeline by Daiichi Sankyo Company, Limited, H1 2015 205
Prostate Cancer Pipeline by DEKK-TEC, Inc., H1 2015 206
Prostate Cancer Pipeline by DexTech Medical AB, H1 2015 207
Prostate Cancer Pipeline by DiaMedica Inc., H1 2015 208
Prostate Cancer Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 209
Prostate Cancer Pipeline by DormaTarg, Inc., H1 2015 210
Prostate Cancer Pipeline by Eisai Co., Ltd., H1 2015 211
Prostate Cancer Pipeline by Eli Lilly and Company, H1 2015 212
Prostate Cancer Pipeline by Emergent BioSolutions Inc., H1 2015 213
Prostate Cancer Pipeline by Enceladus Pharmaceuticals BV, H1 2015 214
Prostate Cancer Pipeline by Endo Pharmaceuticals Inc., H1 2015 215
Prostate Cancer Pipeline by EndoCeutics, Inc., H1 2015 216
Prostate Cancer Pipeline by Endocyte, Inc., H1 2015 217
Prostate Cancer Pipeline by EntreChem, S.L., H1 2015 218
Prostate Cancer Pipeline by Errant Gene Therapeutics, LLC, H1 2015 219
Prostate Cancer Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 220
Prostate Cancer Pipeline by Evgen Limited, H1 2015 221
Prostate Cancer Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 222
Prostate Cancer Pipeline by Ferring International Center S.A., H1 2015 223
Prostate Cancer Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 224
Prostate Cancer Pipeline by Fortress Biotech, Inc., H1 2015 225
Prostate Cancer Pipeline by Fujifilm Corporation, H1 2015 226
Prostate Cancer Pipeline by Galectin Therapeutics, Inc., H1 2015 227
Prostate Cancer Pipeline by Galileo Research s.r.l., H1 2015 228
Prostate Cancer Pipeline by Genelux Corporation, H1 2015 229
Prostate Cancer Pipeline by Genentech, Inc., H1 2015 230
Prostate Cancer Pipeline by Genmab A/S, H1 2015 231
Prostate Cancer Pipeline by GenSpera, Inc., H1 2015 232
Prostate Cancer Pipeline by Glactone Pharma AB, H1 2015 233
Prostate Cancer Pipeline by GlaxoSmithKline Plc, H1 2015 234
Prostate Cancer Pipeline by GlycoMimetics, Inc., H1 2015 235
Prostate Cancer Pipeline by GP Pharm, S.A., H1 2015 236

List of Figures
Number of Products under Development for Prostate Cancer, H1 2015 64
Number of Products under Development for Prostate Cancer Comparative Analysis, H1 2015 65
Number of Products under Development by Companies, H1 2015 66
Number of Products under Investigation by Universities/Institutes, H1 2015 87
Comparative Analysis by Late Stage Development, H1 2015 93
Comparative Analysis by Clinical Stage Development, H1 2015 94
Comparative Analysis by Early Stage Products, H1 2015 95
Assessment by Monotherapy Products, H1 2015 362
Assessment by Combination Products, H1 2015 363
Number of Products by Top 10 Targets, H1 2015 364
Number of Products by Stage and Top 10 Targets, H1 2015 364
Number of Products by Top 10 Mechanism of Actions, H1 2015 382
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 382
Number of Products by Top 10 Routes of Administration, H1 2015 396
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 396
Number of Products by Top 10 Molecule Types, H1 2015 398
Number of Products by Stage and Top 10 Molecule Types, H1 2015 398